Mirum Pharmaceuticals (MIRM) Total Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Liabilities history runs 9 years deep, the most recent figure standing at $648.4 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 41.89% year-over-year to $648.4 million in Q1 2026; TTM through Mar 2026 was $648.4 million, a 41.89% increase from a year earlier, with the FY2025 full-year figure at $528.1 million, up 18.65% from the prior year.
• Total Liabilities advanced to $648.4 million in Q1 2026 per MIRM's latest filing, from $528.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $648.4 million in Q1 2026 and bottomed at $169.2 million in Q1 2022.
• The 5-year median for Total Liabilities is $417.4 million (2024), against an average of $378.0 million.
• Across the five-year window, Total Liabilities jumped 116.95% in 2024 and climbed 9.01% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $210.9 million in 2022, then surged by 88.72% to $398.0 million in 2023, then increased by 11.85% to $445.1 million in 2024, then grew by 18.65% to $528.1 million in 2025, then grew by 22.78% to $648.4 million in 2026.
• Per Business Quant, the three latest MIRM Total Liabilities figures stand at $648.4 million (Q1 2026), $528.1 million (Q4 2025), and $493.1 million (Q3 2025).